Stability and biodistribution of a biodegradable macromolecular MRI contrast agent Gd-DTPA cystamine copolymers (GDCC) in rats.
OBJECTIVE
The aim of this study was to evaluate stability and Gd tissue distribution of a biodegradable macromolecular MRI contrast agent, GDCC.


METHODS
Kinetic stability of GDCC was evaluated based on transmetallation with endogenous metal ions Zn2+ and Cu2+ in rat plasma in comparison with Omniscan, MultiHance and ProHance. In vivo transmetallation of GDCC was evaluated by determining metal content in the urine samples of Spague-Dawley rats. The biodistribution of the agents was determined in rats at 48 h post-injection.


RESULTS
A new method of using ultrafiltration was developed for study of kinetic stability against transmetallation of Gd(III)-based MRI contrast agents. Both in vitro and in vivo stability of the contrast agents towards transmetallation with Zn2+ were in the order of ProHance > MultiHance approximately GDCC > Omniscan. No significant transmetallation with Cu2+ was observed for the contrast agents. GDCC had comparable retention to the control agents in most organs and tissues with slightly high retention in the liver and kidneys at 48 h post-injection.


CONCLUSIONS
Ultrafiltration is efficient and accurate for characterizing the kinetic stability of Gd(III)-based MRI contrast agents. The novel biodegradable macromolecular contrast agent GDCC is promising for further development for contrast enhanced MRI.
Wu
Xueming
X
Department of Biomedical Engineering, Case Western Reserve University, Wickenden Building, Room 427, 10900 Euclid Avenue, Cleveland, Ohio 44106-7207, USA.
Zong
Yuda
Y
Ye
Zhen
Z
Lu
Zheng-Rong
ZR
D000818:Animals; D001682:Biological Availability; D003287:Contrast Media / Q000737:chemistry* / Q000493:pharmacokinetics; D003538:Cystamine / Q000737:chemistry / Q000493:pharmacokinetics; D004355:Drug Stability; D019786:Gadolinium DTPA / Q000737:chemistry* / Q000493:pharmacokinetics; D008279:Magnetic Resonance Imaging; D008297:Male; D009942:Organometallic Compounds / Q000737:chemistry / Q000493:pharmacokinetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D014018:Tissue Distribution
D003287:Contrast Media; D009942:Organometallic Compounds; D019786:Gadolinium DTPA; D003538:Cystamine
Eur Radiol. 2008 Oct;18(10):2164-73
18545998
Biometals. 2008 Aug;21(4):469-90
18344005
Magn Reson Med. 2008 Dec;60(6):1347-52
19025902
Clin J Am Soc Nephrol. 2007 Mar;2(2):200-2
17699407
Br J Radiol. 2007 Feb;80(950):73-6
17392401
Invest Radiol. 1996 Oct;31(10):619-24
8889650
Invest Radiol. 2008 Jan;43(1):65-75
18097279
J Magn Reson Imaging. 2000 Jun;11(6):694-701
10862070
J Magn Reson Imaging. 2008 May;27(5):955-62
18425843
Fundam Clin Pharmacol. 2006 Dec;20(6):563-76
17109649
Toxicol Pathol. 1997 May-Jun;25(3):245-55
9210255
Invest Radiol. 1995 Jun;30(6):372-80
7490190
Pharm Res. 2008 Sep;25(9):2002-11
18584312
Magn Reson Med. 2004 Jan;51(1):27-34
14705042
Curr Opin Rheumatol. 2006 Nov;18(6):614-7
17053507
Mol Pharm. 2010 Feb 1;7(1):41-8
19958031
Invest Radiol. 1996 Dec;31(12):739-42
8970874
Clin J Am Soc Nephrol. 2007 Mar;2(2):258-63
17699422
Pharm Res. 2006 Aug;23(8):1736-42
16850267
Invest Radiol. 2001 Feb;36(2):115-22
11224760
Pharm Res. 2009 Sep;26(9):2202-8
19597972
Pharm Res. 2005 Apr;22(4):596-602
15846467
Chemistry. 2000 Feb 18;6(4):719-24
10807182
Invest Radiol. 2003 Oct;38(10):662-8
14501494
Radiat Med. 2005 Aug;23(5):322-6
16342903
Magn Reson Imaging. 1991;9(3):409-15
1881260